Literature DB >> 33994608

Optimal treatment regimes for competing risk data using doubly robust outcome weighted learning with bi-level variable selection.

Yizeng He1, Soyoung Kim1, Mi-Ok Kim2, Wael Saber3, Kwang Woo Ahn1.   

Abstract

The goal of the optimal treatment regime is maximizing treatment benefits via personalized treatment assignments based on the observed patient and treatment characteristics. Parametric regression-based outcome learning approaches require exploring complex interplay between the outcome and treatment assignments adjusting for the patient and treatment covariates, yet correctly specifying such relationships is challenging. Thus, a robust method against misspecified models is desirable in practice. Parsimonious models are also desired to pursue a concise interpretation and to avoid including spurious predictors of the outcome or treatment benefits. These issues have not been comprehensively addressed in the presence of competing risks. Recognizing that competing risks and group variables are frequently present, we propose a doubly robust estimation with adaptive L 1 penalties to select important variables at both group and within-group levels for competing risks data. The proposed method is applied to hematopoietic cell transplantation data to personalize the graft source choice for treatment-related mortality (TRM). While the existing medical literature attempts to find a uniform solution ignoring the heterogeneity of the graft source effects on TRM, the analysis results show the effect of the graft source on TRM could be different depending on the patient-specific characteristics.

Entities:  

Keywords:  Competing risks; bi-level variable selection; optimal treatment regime; personalized medicine

Year:  2021        PMID: 33994608      PMCID: PMC8117077          DOI: 10.1016/j.csda.2021.107167

Source DB:  PubMed          Journal:  Comput Stat Data Anal        ISSN: 0167-9473            Impact factor:   2.035


  21 in total

1.  A nonidentifiability aspect of the problem of competing risks.

Authors:  A Tsiatis
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

Review 2.  Allogeneic transplantation: peripheral blood vs. bone marrow.

Authors:  William I Bensinger
Journal:  Curr Opin Oncol       Date:  2012-03       Impact factor: 3.645

3.  Comparison of the marginal hazard model and the sub-distribution hazard model for competing risks under an assumed copula.

Authors:  Takeshi Emura; Jia-Han Shih; Il Do Ha; Ralf A Wilke
Journal:  Stat Methods Med Res       Date:  2019-12-22       Impact factor: 3.021

Review 4.  Practical methods for competing risks data: a review.

Authors:  Giorgos Bakoyannis; Giota Touloumi
Journal:  Stat Methods Med Res       Date:  2011-01-07       Impact factor: 3.021

5.  On Sparse representation for Optimal Individualized Treatment Selection with Penalized Outcome Weighted Learning.

Authors:  Rui Song; Michael Kosorok; Donglin Zeng; Yingqi Zhao; Eric Laber; Ming Yuan
Journal:  Stat       Date:  2015

6.  A Proportional Hazards Regression Model for the Sub-distribution with Covariates Adjusted Censoring Weight for Competing Risks Data.

Authors:  Peng He; Frank Eriksson; Thomas H Scheike; Mei-Jie Zhang
Journal:  Scand Stat Theory Appl       Date:  2015-06-05       Impact factor: 1.396

7.  Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data.

Authors:  Rebecca Hager; Anastasios A Tsiatis; Marie Davidian
Journal:  Biometrics       Date:  2018-05-18       Impact factor: 2.571

8.  A group bridge approach for variable selection.

Authors:  Jian Huang; Shuange Ma; Huiliang Xie; Cun-Hui Zhang
Journal:  Biometrika       Date:  2009-06       Impact factor: 2.445

9.  On restricted optimal treatment regime estimation for competing risks data.

Authors:  Jie Zhou; Jiajia Zhang; Wenbin Lu; Xiaoming Li
Journal:  Biostatistics       Date:  2021-04-10       Impact factor: 5.899

10.  A comparison of model selection methods for prediction in the presence of multiply imputed data.

Authors:  Le Thi Phuong Thao; Ronald Geskus
Journal:  Biom J       Date:  2018-10-23       Impact factor: 2.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.